Logo image of EVOK

EVOKE PHARMA INC (EVOK) Stock Fundamental Analysis

NASDAQ:EVOK - Nasdaq - US30049G3020 - Common Stock - Currency: USD

5.07  -0.19 (-3.53%)

Fundamental Rating

4

Taking everything into account, EVOK scores 4 out of 10 in our fundamental rating. EVOK was compared to 194 industry peers in the Pharmaceuticals industry. EVOK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EVOK is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EVOK has reported negative net income.
EVOK had a negative operating cash flow in the past year.
In the past 5 years EVOK always reported negative net income.
In the past 5 years EVOK always reported negative operating cash flow.
EVOK Yearly Net Income VS EBIT VS OCF VS FCFEVOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

EVOK has a Return On Assets (-43.43%) which is in line with its industry peers.
With a Return On Equity value of -140.11%, EVOK is not doing good in the industry: 64.86% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -43.43%
ROE -140.11%
ROIC N/A
ROA(3y)-86.8%
ROA(5y)-102.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVOK Yearly ROA, ROE, ROICEVOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400

1.3 Margins

The Gross Margin of EVOK (96.55%) is better than 97.84% of its industry peers.
EVOK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVOK Yearly Profit, Operating, Gross MarginsEVOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, EVOK has less shares outstanding
Compared to 5 years ago, EVOK has less shares outstanding
EVOK has a worse debt/assets ratio than last year.
EVOK Yearly Shares OutstandingEVOK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
EVOK Yearly Total Debt VS Total AssetsEVOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

EVOK has an Altman-Z score of -12.56. This is a bad value and indicates that EVOK is not financially healthy and even has some risk of bankruptcy.
EVOK has a worse Altman-Z score (-12.56) than 78.38% of its industry peers.
EVOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.56
ROIC/WACCN/A
WACCN/A
EVOK Yearly LT Debt VS Equity VS FCFEVOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M

2.3 Liquidity

A Current Ratio of 1.44 indicates that EVOK should not have too much problems paying its short term obligations.
EVOK's Current ratio of 1.44 is on the low side compared to the rest of the industry. EVOK is outperformed by 76.22% of its industry peers.
A Quick Ratio of 1.39 indicates that EVOK should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.39, EVOK is not doing good in the industry: 69.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.44
Quick Ratio 1.39
EVOK Yearly Current Assets VS Current LiabilitesEVOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

EVOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.65%, which is quite impressive.
Looking at the last year, EVOK shows a very strong growth in Revenue. The Revenue has grown by 100.40%.
Measured over the past years, EVOK shows a very strong growth in Revenue. The Revenue has been growing by 537.46% on average per year.
EPS 1Y (TTM)59.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.64%
Revenue 1Y (TTM)100.4%
Revenue growth 3Y537.46%
Revenue growth 5YN/A
Sales Q2Q%69.82%

3.2 Future

The Earnings Per Share is expected to grow by 27.95% on average over the next years. This is a very strong growth
EVOK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 84.05% yearly.
EPS Next Y85.48%
EPS Next 2Y42.04%
EPS Next 3Y27.95%
EPS Next 5YN/A
Revenue Next Year95.11%
Revenue Next 2Y97.31%
Revenue Next 3Y84.05%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EVOK Yearly Revenue VS EstimatesEVOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
EVOK Yearly EPS VS EstimatesEVOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -100 -200 -300

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

EVOK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 10.36 indicates a reasonable valuation of EVOK.
EVOK's Price/Forward Earnings ratio is rather cheap when compared to the industry. EVOK is cheaper than 87.03% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.68. EVOK is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 10.36
EVOK Price Earnings VS Forward Price EarningsEVOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVOK Per share dataEVOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EVOK's earnings are expected to grow with 27.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.04%
EPS Next 3Y27.95%

More info and screens

0

5. Dividend

5.1 Amount

EVOK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOKE PHARMA INC

NASDAQ:EVOK (2/21/2025, 8:16:23 PM)

5.07

-0.19 (-3.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-05 2025-03-05/amc
Inst Owners14.7%
Inst Owner Change4.87%
Ins Owners4.43%
Ins Owner Change0%
Market Cap7.55M
Analysts82.86
Price Target18.36 (262.13%)
Short Float %2.94%
Short Ratio1.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.58%
Min EPS beat(2)-142.52%
Max EPS beat(2)-26.63%
EPS beat(4)1
Avg EPS beat(4)-41.05%
Min EPS beat(4)-142.52%
Max EPS beat(4)20.63%
EPS beat(8)4
Avg EPS beat(8)-16.42%
EPS beat(12)6
Avg EPS beat(12)-15.13%
EPS beat(16)9
Avg EPS beat(16)-8.59%
Revenue beat(2)0
Avg Revenue beat(2)-19.3%
Min Revenue beat(2)-22.51%
Max Revenue beat(2)-16.09%
Revenue beat(4)1
Avg Revenue beat(4)-14.59%
Min Revenue beat(4)-22.51%
Max Revenue beat(4)0.66%
Revenue beat(8)3
Avg Revenue beat(8)-8.56%
Revenue beat(12)4
Avg Revenue beat(12)-8.49%
Revenue beat(16)6
Avg Revenue beat(16)-5.9%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.36
P/S 0.88
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)-10.99
EYN/A
EPS(NY)0.49
Fwd EY9.66%
FCF(TTM)-3.57
FCFYN/A
OCF(TTM)-3.57
OCFYN/A
SpS5.78
BVpS2.94
TBVpS2.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.43%
ROE -140.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.55%
FCFM N/A
ROA(3y)-86.8%
ROA(5y)-102.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.44
Quick Ratio 1.39
Altman-Z -12.56
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.64%
EPS Next Y85.48%
EPS Next 2Y42.04%
EPS Next 3Y27.95%
EPS Next 5YN/A
Revenue 1Y (TTM)100.4%
Revenue growth 3Y537.46%
Revenue growth 5YN/A
Sales Q2Q%69.82%
Revenue Next Year95.11%
Revenue Next 2Y97.31%
Revenue Next 3Y84.05%
Revenue Next 5YN/A
EBIT growth 1Y18.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.44%
OCF growth 3YN/A
OCF growth 5YN/A